Protocol Ledger

NCT06230523 · Phase II · COMPLETED

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Interventional Phase II clinical trial protocol NCT06230523 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-02-05 Enrollment: 263 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06230523
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)263 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06230523
Protocol FieldVerified Registry Value
NCT IdentifierNCT06230523
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment263 participants (ACTUAL)
Registered Start Date2024-02-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06230523
Hospital Research SiteLocationSite Profile
Velocity Clinical Research (Huntington Park)Huntington Park, CAOpen Hospital Dossier ->
Diablo Clinical Research IncWalnut Creek, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI